Replimune Group Balansräkning Hälsa

Finansiell hälsa kriterier kontrolleras 4/6

Replimune Group har ett totalt eget kapital på $166.2M och en total skuld på $83.3M vilket ger sin skuldsättningsgrad till 50.1%. Dess totala tillgångar och totala skulder är $332.4M respektive $166.2M.

Viktig information

50.14%

Skuldsättning i förhållande till eget kapital

US$83.31m

Skuld

Räntetäckningsgrad	n/a
Kontanter	US$268.89m
Eget kapital	US$166.16m
Summa skulder	US$166.23m
Totala tillgångar	US$332.39m

Nya uppdateringar om finansiell hälsa

Analysartikel • Feb 08

Recent updates

Seeking Alpha • Jun 30

Replimune: Stock Buoyant On Third Try At RP1 Approval - FDA AdCom May Be Crucial

Summary Replimune Group, Inc. faces a pivotal FDA AdCom for RP1 after two prior rejections, with a final FDA approval decision expected August 2, 2026. RP1 demonstrated a 34% ORR and median overall survival of 32.9 months in anti-PD-1-failed melanoma, but trial design concerns persist. REPL stock has surged over 135% since April as FDA leadership changes and collaborative dialogue opened a path for BLA resubmission. I assign a Hold rating on REPL stock due to regulatory uncertainty, persistent trial design criticisms, and questions around commercial viability versus peers. Read the full article on Seeking Alpha

Analysartikel • Feb 08

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Analysartikel • Aug 01

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Seeking Alpha • Apr 28

Replimune: Scope Goes Beyond That Of RP1 Oncolytic Targeting For Melanoma

Summary Replimune Group, Inc.'s BLA of RP1 + OPDIVO in advanced melanoma received an FDA Priority Review, with a PDUFA date set for July 22, 2025. RP2, adding an anti-CTLA-4 component, is being tested in metastatic uveal melanoma and 2nd-line metastatic hepatocellular carcinoma patients. Financially, Replimune has $536.5 million in cash, but REPL will likely need additional funding within the next 12 months. The global liver cancer drugs market is expected to reach $14.9 billion by 2031. Read the full article on Seeking Alpha

Analysartikel • Apr 11

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Seeking Alpha • Feb 12

Replimune: A Misunderstood Contender In Oncolytics

Summary Replimune Group's solid cash position and strategic focus on niche oncology markets position it for potential success, despite market volatility and past trial setbacks. The company's RP1 and RP2 platforms target unmet needs in melanoma and other cancers, with promising data and regulatory momentum supporting their potential. The FDA's Priority Review and Breakthrough Therapy designations for RP1 underscore its potential to reshape second-line melanoma treatment and expedite market entry. Despite skepticism about oncolytic viruses, Replimune's approach and collaborations with big pharma could yield significant commercial opportunities if clinical data remains strong. Read the full article on Seeking Alpha

Seeking Alpha • Nov 29

Replimune: RPL1 BLA Submission Under AA Pathway Makes It A Must Watch

Summary Replimune has submitted its BLA of RP1 + Opdivo for the treatment of advanced melanoma patients previously treated with an anti-PD1 containing regimen. The phase 3 confirmatory IGNYTE-3 study is underway to prove yet again that RP1 + Opdivo is able to help these patients with advanced melanoma and to keep the drug marketed. The global melanoma therapeutics market size is projected to reach $17.93 billion by 2034. RP2 is another drug in the company's pipeline which is being developed other than target metastatic uveal melanoma and Hepatocellular Carcinoma patients. Read the full article on Seeking Alpha

Analysartikel • Nov 23

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Seeking Alpha • Sep 03

Replimune: Strong Data In A Highly Differentiated Space

Summary Replimune's RP1, an oncolytic immuno-gene therapy, shows promise with a 31.4% ORR in phase 2 trials for post PD-1 melanoma and non-melanoma skin cancers. RP2, adding an anti-CTLA-4 component to RP1, demonstrated a 29.4% ORR in phase 1 trials, with durable responses in difficult-to-treat tumors. Despite competitive challenges and a failed CSCC trial, Replimune's cash runway supports its accelerated approval and phase 3 trials, making it an attractive investment. RP1 and RP2 together could be a game-changer, offering a compelling opportunity at current low stock prices. Read the full article on Seeking Alpha

Analysartikel • Aug 16

Is Replimune Group (NASDAQ:REPL) Using Debt Sensibly?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Seeking Alpha • May 22

Replimune: Continuing To Justify The Bear Thesis (For Now)

Summary Replimune Group, Inc.'s stock has fallen 35% in 2024, and an inflection point is not expected yet. The company is working on RP1, an oncolytic virus therapy, and has shared positive results from their ARTACUS trial. Replimune plans to submit a BLA for RP1 approval in melanoma, but this is far from guaranteed, especially in 2024. Read the full article on Seeking Alpha

Analysartikel • Feb 06

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...

Seeking Alpha • Jan 23

Replimune: The Fall Is Justified, As Virus Therapy Fails Again In Cancer

Summary Replimune Group is developing virus-based treatments for solid tumors, particularly skin cancer. The company's RP1 treatment did not show significant improvement in response rates compared to standard care in a phase 1/2 study, though there is a signal of something buried therein. Replimune plans to initiate a confirmatory study for RP1 in melanoma patients and is also developing RP2 for uveal melanoma. Read the full article on Seeking Alpha

Analysartikel • Dec 25

Calculating The Intrinsic Value Of Replimune Group, Inc. (NASDAQ:REPL)

Key Insights The projected fair value for Replimune Group is US$9.64 based on 2 Stage Free Cash Flow to Equity Current...

Analysartikel • Jul 13

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Analysartikel • Apr 05

Is Replimune Group (NASDAQ:REPL) Using Debt In A Risky Way?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Analysartikel • Jan 06

A Look At The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)

Key Insights Replimune Group's estimated fair value is US$25.6 based on 2 Stage Free Cash Flow to Equity Current share...

Analys av finansiell ställning

Kortfristiga skulder: REPL s kortfristiga tillgångar ( $279.1M ) överstiger dess kortfristiga skulder ( $58.2M ).

Långfristiga skulder: REPL s kortfristiga tillgångar ( $279.1M ) överstiger dess långfristiga skulder ( $108.0M ).

Skuld till eget kapital Historik och analys

Skuldnivå: REPL har mer kontanter än sin totala skuld.

Minska skulden: REPL s skuldsättningsgrad har ökat från 0% till 50.1% under de senaste 5 åren.

Balansräkning

Analys av kontantbanan

För företag som i genomsnitt har gått med förlust tidigare bedömer vi om de har minst 1 års kassaflöde.

Stabil Cash Runway: REPL har mindre än ett år av cash runway baserat på dess nuvarande fria kassaflöde.

Prognos Cash Runway: REPL har tillräckligt med kontanter under 1.9 år om det fria kassaflödet fortsätter att minska i historiska takter på 26.8

Upptäck friska företag

Företagsanalys och finansiella data Status

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2026/07/06 09:08
Aktiekurs vid dagens slut	2026/07/06 00:00
Intäkter	2026/03/31
Årlig intjäning	2026/03/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

^* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Replimune Group, Inc. bevakas av 12 analytiker. 5 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

Analytiker	Institution
Clarence Powell	BMO Capital Markets Equity Research
Evan Seigerman	BMO Capital Markets Equity Research
Guyn Kim	BMO Capital Markets Equity Research

Replimune Group Balansräkning Hälsa

Finansiell hälsa kriterier kontrolleras 4/6

Viktig information

Nya uppdateringar om finansiell hälsa

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Is Replimune Group (NASDAQ:REPL) Using Debt Sensibly?

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Recent updates

Now 24% overvalued after recent price rise

FDA Review Accepted for Replimune RP1 in Melanoma With August 2026 Decision Target

Replimune: Stock Buoyant On Third Try At RP1 Approval - FDA AdCom May Be Crucial

Consensus revenue estimates decrease by 41%

Replimune Group, Inc. Announces U.S. Food and Drug Administration Acceptance Of RP1 Biologics License Application Resubmission For Advanced Melanoma

Replimune Group Presents Three-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial of RP1 Plus Nivolumab in Patients with Anti-PD-1-Failed Melanoma

Replimune BLA Resubmission for RP1 Prioritized by FDA as Survival Data Impresses

Replimune Group Announces Planned RP1 BLA Resubmission Following Discussion With FDA

Now 71% overvalued after recent price rise

Now 25% undervalued after recent price drop

Price target decreased by 20% to US$10.00

Replimune Group, Inc. Receives Complete Response Letter From FDA For RP1 Biologics License Application For Treatment Of Advanced Melanoma

Chief Commercial Officer notifies of intention to sell stock

New minor risk - Share price stability

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

New minor risk - Financial position

CEO & Director notifies of intention to sell stock

Price target increased by 9.3% to US$12.57

Replimune Group, Inc. Presents Late-Breaking Abstract and Additional Posters on Rp1 At 40Th Annual Meeting of the Society for the Immunotherapy of Cancer (Sitc 2025)

Consensus revenue estimates increase by 28%

Replimune Group, Inc. Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma Prescription Drug User Fee Act (PDUFA) Target Action Date Set for April 10, 2026

Replimune Group, Inc. Highlights Acral Melanoma Data for Rp1 Plus Nivolumab At the ESMO Congress 2025

Replimune Provides Update Following Type A Meeting with FDA

Investor Lawsuit Targets Replimune (REPL) After FDA Deems RP1 Trial Inadequate - Hagens Berman

Price target decreased by 13% to US$4.86

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

Replimune Group, Inc., Annual General Meeting, Sep 03, 2025

Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Replimune Group, Inc

New major risk - Share price stability

Price target decreased by 48% to US$11.38

Replimune Group, Inc. Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma

Replimune Group, Inc. Presents New Analyses from the Ignyte Study of Rp1 Plus Nivolumab in Anti-Pd-1 Failure Melanoma At the 2025 American Society of Clinical Oncology Annual Meeting

Replimune Group, Inc. to Report Q4, 2025 Results on May 22, 2025

New minor risk - Share price stability

Replimune: Scope Goes Beyond That Of RP1 Oncolytic Targeting For Melanoma

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

Replimune Group, Inc. Appoints Michael Goller to Its Board of Directors

Replimune: A Misunderstood Contender In Oncolytics

Replimune Group, Inc. Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma

New major risk - Shareholder dilution

Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials

Price target increased by 11% to US$18.38

CEO & Director notifies of intention to sell stock

Replimune: RPL1 BLA Submission Under AA Pathway Makes It A Must Watch

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $139.999007 million.

Replimune Group, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

New minor risk - Share price stability

Replimune Group, Inc. Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway

Replimune Presents Late-Breaking Abstract Featuring Data from Ignyte Clinical Trial of Rp1 Combined with Nivolumab in Anti-Pd1 Failed Melanoma At the 39Th Annual Meeting of the Society for Immunotherapy of Cancer (Sitc 2024)

Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-Pd1 Failed Melanoma At European Society for Medical Oncology Congress 2024

Replimune: Strong Data In A Highly Differentiated Space

Chief Financial Officer recently sold US$91k worth of stock

Is Replimune Group (NASDAQ:REPL) Using Debt Sensibly?

Consensus revenue estimates decrease by 50%, EPS upgraded

Replimune Group, Inc. Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma

Price target increased by 8.2% to US$14.67

Replimune Group, Inc., Annual General Meeting, Sep 04, 2024

Replimune Group, Inc. announced that it expects to receive $100.000032 million in funding

Chief Medical Officer notifies of intention to sell stock

Price target increased by 9.2% to US$14.56

Replimune Group, Inc. Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of Rp1 Plus Nivolumab in Anti-Pd1 Failed Melanoma

New minor risk - Share price stability

Replimune Presents Positive Data from Rp1 and Rp2 Clinical Programs At the 2024 American Society of Clinical Oncology (Asco) Annual Meeting

Replimune: Continuing To Justify The Bear Thesis (For Now)

Executive Chairman recently sold US$245k worth of stock

Replimune Group, Inc. Announces Management Changes

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Replimune: The Fall Is Justified, As Virus Therapy Fails Again In Cancer